Abstract

Abstract

Recent evidence, including a 2026 review in The Lancet, confirms that mRNA vaccines are robustly effective against infectious diseases and show strong promise for cancer immunotherapy, particularly in melanoma and in combination with immune checkpoint inhibitors. However, critical barriers remain: delivery to the right tissue, control of the treatment environment, and reproducible measurement of immune response and toxicity.

The Caldwell Open‑Hardware Oncology Research Platform (C‑OHRP v1.0) is a modular, non‑clinical research platform that integrates the most relevant elements of the Caldwell open‑hardware portfolio to improve the viability of mRNA cancer vaccine and immunotherapy programs. It does not claim to cure cancer or achieve 100% success. Instead, it aims to make cancer research more controlled, measurable, and reproducible by adding:

  • Non‑invasive, ultrasound‑enhanced, closed‑loop delivery assist hardware (inspired by ONRS, ONRS‑AMD, APOTS‑Ω, POAV‑Clamp, CNIMDR).

  • Closed‑loop sensing and control using CMRS‑1, Arachne thermal management, APR AI, and CICIS infrastructure.

  • A modular skid, telemetry, and deployment framework using CMLRS and CORES.

  • A research roadmap that integrates the existing GCI Oncology Suite and related biomedical platforms.

C‑OHRP is explicitly intended as a research testbed, not a clinical treatment. It is designed to help labs and clinics evaluate mRNA cancer vaccines, immunotherapy combinations, and other biologics in a more stable, monitored, and reproducible hardware environment.

Core objective

The objective of C‑OHRP v1.0 is to:

  • Improve the engineering reliability of cancer vaccine and immunotherapy research hardware.

  • Improve the control and measurement of the treatment environment (temperature, acoustic exposure, timing, and response signals).

  • Provide a modular, testable platform that can be built and iterated by researchers without requiring proprietary instruments.

  • Use the most realistic parts of the Caldwell portfolio: controlled delivery, sensing, and thermal management, not “field cure” claims.

This platform cannot make mRNA vaccines work that do not already work. It can only make the research environment more stable and the data more trustworthy.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Download

Share

COinS